Clinical trial NCT03601819: Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Official title: Phase Ib, Open Label, Single Center Study of Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Chronic Lymphocytic Leukemia
Lymphoproliferative Disorders
Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Keywords: Relapsed
Refractory
MyD88
JAK2
JAK3
TYK2
IRAK1
CLL
SMZL
LPL
WM
MCL
CTCL
PTCL
Lead sponsor: University of Michigan Rogel Cancer Center
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of any of the following:

  1. Relapsed/refractory cutaneous (stage IIb-IV by ISCL/EORTC staging criteria) or peripheral T-cell lymphoma with progression after the last line of therapy and refractory to/intolerant of or have a contraindication to all established therapies known to provide clinical benefit (including brentuximab vedotin for patients with anaplastic large cell lymphomas) OR
  2. Chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL), Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) or mantle cell lymphoma (MCL) with disease progression on ibrutinib or who discontinue ibrutinib due to toxicity/intolerance. In addition, patients should be refractory to/intolerant of or have a contraindication to all established therapies known to provide clinical benefit OR
  3. Any lymphoproliferative disorder who have failed at least 2 prior therapies and are refractory to/intolerant of or have a contraindication to all established therapies known to provide clinical benefit and have had mutational analysis or sequencing studies performed in a CLIA certified laboratory demonstrating a mutation or gene fusion involving MyD88, JAK2, JAK3, TYK2, or IRAK1 that are known or suspected to be "activating" (gain-of-function).
* Age ≥ 18 at time of enrollment
* ECOG ≤ 2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.)
* Adequate organ and marrow function as defined in the protocol
* Ability to take oral medication without crushing, dissolving or chewing tablets.
* In the investigator's opinion, the patient requires immediate treatment.
* Ability to understand and the willingness to sign a written informed consent.
* In the investigator's opinion, the patient has the ability to communicate satisfactorily with the investigator and the study team, to participate fully in the study, and comply with all requirements.

Exclusion Criteria:

* History of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study
* Pregnant or breast feeding women
* Unwilling or unable to use a medically acceptable form of contraception during the time of participation in the trial (sexual abstinence is permissible) unless documented successful vasectomy, hysterectomy, bilateral oophorectomy or post-menopausal for at least 2 years
* Uncontrolled current illness, including, but not limited to the following: Ongoing or active infections requiring intravenous antimicrobials; symptomatic congestive heart failure defined as NYHA class II, III or IV (Appendix II); unstable angina pectoris within 6 months of study enrollment; unstable cardiac arrhythmia; history of myocardial infarction, stroke or intracranial hemorrhage within 6 months prior to enrollment; moderate to severe hepatic impairment (Child-Pugh class B or C); psychiatric illness or social situations that would limit compliance with study requirements
* Known HIV infection
* Known positive Hepatitis B surface antigen or Hep C virus
* Recent (within 21 days of initiation of therapy, day 1) major surgery
* Less than 14 days have elapsed since last radiation therapy or chemotherapy treatment or patient has not recovered from all clinically significant treatment-related toxicity; less than 90 days have passed since date of autologous stem cell transplant and patient has not recovered to ≤grade 1 toxicity related to this procedure
* Use of systemic steroids (oral, inhaled, nasal, topical) at a dose less \> 10 mg/day of prednisone
* Prior treatment with pacritinib
* Uncontrolled autoimmune hemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP). Coombs positivity in absence of hemolysis is not an exclusion.
* Requires anticoagulation with heparin, warfarin or equivalent Vit K antagonist
* History of significant bleeding (≥Grade 2 by CTCAE) history or complications (including bleeding that may have occurred while on ibrutinib)
* Hypersensitivity or allergic reaction to compounds related to pacritinib
* Treatment with potent CYP450 inducers and strong CYP3A4 inhibitors for which no alternative is available; treatment with strong CYP450 inducers or strong CYP3A4 inhibitors within 2 weeks of initiation of therapy, day 1
* Concurrent administration of QTc prolonging agents; significant QTc prolonging agents must be stopped within 5 half-lives of day 1.
* Any gastrointestinal or metabolic condition that could interfere with the absorption of oral medication

Primary outcomes:
measure: Rate of dose limiting toxicities (DLT)
timeFrame: At 28 days
Secondary outcomes:
measure: The proportion of patients that respond to treatment
timeFrame: Up to 2 years
measure: The proportion of patients that experience a complete response (CR)
timeFrame: Up to 2 years
measure: Duration of response (DOR)
timeFrame: Up to 2 years
measure: Time to next treatment
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Rogel Cancer Center
state: Michigan
Study officials:
affiliation: University of Michigan Rogel Cancer Center
name: Ryan Wilcox, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: